High dose melphalan in primary systemic amyloidosis: status quo?
Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece. ekastritis@gmail.com
Efstathios
E
Kastritis
Meletios A
MA
Dimopoulos
D000686:Amyloidosis / Q000188:drug therapy / Q000401:mortality; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage; D004305:Dose-Response Relationship, Drug; D005500:Follow-Up Studies; D006801:Humans; D000075363:Immunoglobulin Light-chain Amyloidosis; D008495:Medical Oncology / Q000639:trends; D008558:Melphalan / Q000008:administration & dosage*; D005791:Patient Care / Q000639:trends; D016896:Treatment Outcome
D018906:Antineoplastic Agents, Alkylating; D008558:Melphalan